Marc Botteman

Deep Dive

Revealing the true value of new cancer drugs to payers

Marc Botteman and Ben van Hout from Pharmerit International discuss how to navigate the value challenges of new cancer treatments like CAR-T with payers.

News

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks